No. S 279
Poisons Act
Poisons (Amendment No. 3) Rules 1999
In exercise of the powers conferred by section 20(1) of the Poisons Act, the Minister for Health hereby makes the following Rules:
Citation and commencement
1.  These Rules may be cited as the Poisons (Amendment No. 3) Rules 1999 and shall be deemed to have come into operation on 10th June 1999.
Amendment of First Schedule
2.  The First Schedule to the Poisons Rules (R 1) is amended —
(a)by inserting, immediately below the item “Camazepam”, the following item:
Candesartan; its salts; its esters; their salts”;
(b)by inserting, immediately below the item “Cantharidates; except substances containing less than the equivalent of 0.01% of cantharidin”, the following item:
Capecitabine”;
(c)by inserting, immediately below the item “Dacarbazine”, the following item:
Daclizumab”;
(d)by inserting, immediately below the item “Iproniazid; its salts”, the following item:
Irbesartan”;
(e)by inserting, immediately below the item “Levodopa”, the following item:
Levodropropizine”;
(f)by inserting, immediately below the item “Midazolam; its salts”, the following item:
Miglitol”;
(g)by inserting, immediately below the item “Pargyline; its salts”, the following item:
Parnaparin; its salts”;
(h)by inserting, immediately below the item “Sevoflurane”, the following item:
Sildenafil; its salts”;
(i)by inserting, immediately below the item “Tinidazole”, the following item:
Tinzaparin; its salts”;
(j)by inserting, immediately below the item “Tirilazad; its salts”, the following item:
Tirofiban; its salts”; and
(k)by deleting the item “Ursodeoxycholic acid; its salts; its esters; their salts Valaciclovir; its salts”, and substittuing the following items:
Ursodeoxycholic acid; its salts; its esters; their salts
Vaccines, sera, toxoids, antitoxoids, immunoglobulins and antigens for human administration
Valaciclovir; its salts”.
Amendment of Third Schedule
3.  The Third Schedule to the Poisons Rules is amended —
(a)by inserting, immediately below the item “Camazepam”, the following item:
Candesartan; its salts; its esters; their salts”;
(b)by inserting, immediately below the item “Candicidin; its salts; its esters; their salts”, the following item:
Capecitabine”;
(c)by inserting, immediately below the item “Dacarbazine”, the following item:
Daclizumab”;
(d)by inserting, immediately below the item “Iproniazid; its salts”, the following item:
Irbesartan”;
(e)by inserting, immediately below the item “Midazolam; its salts”, the following item:
Miglitol”;
(f)by deleting the item “Nicotine; its salts; its quarternary compounds; their salts”, and substituting the following item:
Nicotine; its salts; its quarternary compounds; their salts except when contained in transdermal patches”;
(g)by inserting, immediately below the item “Pargyline; its salts”, the following item:
Parnaparin; its salts”;
(h)by inserting, immediately below the item “Sertraline; its salts”, the following item:
Sildenafil; its salts”;
(i)by inserting, immediately below the item “Tinidazole”, the following item:
Tinzaparin; its salts”;
(j)by inserting, immediately below the item “Tirilazad; its salts”, the following item:
Tirofiban; its salts”; and
(k)by inserting, immediately below the item “Ursodeoxycholic acid; its salts; its esters; their salts”, the following item:
Vaccines, sera, toxoids, antitoxoids, immunoglobulins and antigens for human administration”.
[G.N. Nos. S 632/98; S 51/99; S 177/99]
Made this 12th day of June 1999.
MOSES LEE
Second Permanent Secretary,
Ministry of Health,
Singapore.
[PD(DAD) 78:1 Vol 3; AG/LEG/SL/234/97/1 Vol. 2]